215 related articles for article (PubMed ID: 28741382)
1. Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.
Yabe D; Hamamoto Y; Seino Y; Kuwata H; Kurose T; Seino Y
Expert Opin Drug Saf; 2017 Oct; 16(10):1211-1218. PubMed ID: 28741382
[TBL] [Abstract][Full Text] [Related]
2. Luseogliflozin for the treatment of type 2 diabetes.
Seino Y
Expert Opin Pharmacother; 2014 Dec; 15(18):2741-9. PubMed ID: 25359155
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.
Yabe D; Iwasaki M; Kuwata H; Haraguchi T; Hamamoto Y; Kurose T; Sumita K; Yamazato H; Kanada S; Seino Y
Diabetes Obes Metab; 2017 May; 19(5):739-743. PubMed ID: 27990776
[TBL] [Abstract][Full Text] [Related]
4. Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?
Pafili K; Papanas N
Expert Opin Pharmacother; 2015 Mar; 16(4):453-6. PubMed ID: 25605060
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.
Sakai S; Kaku K; Seino Y; Inagaki N; Haneda M; Sasaki T; Fukatsu A; Kakiuchi H; Samukawa Y
Clin Ther; 2016 Apr; 38(4):843-862.e9. PubMed ID: 27021608
[TBL] [Abstract][Full Text] [Related]
6. The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT).
Haraguchi A; Shigeno R; Horie I; Morimoto S; Ito A; Chiba K; Kawazoe Y; Tashiro S; Miyamoto J; Sato S; Yamamoto H; Osaki M; Kawakami A; Abiru N
Trials; 2020 May; 21(1):379. PubMed ID: 32370806
[TBL] [Abstract][Full Text] [Related]
7. Luseogliflozin: first global approval.
Markham A; Elkinson S
Drugs; 2014 Jun; 74(8):945-50. PubMed ID: 24848756
[TBL] [Abstract][Full Text] [Related]
8. Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus.
Jinnouchi H; Nozaki K; Watase H; Omiya H; Sakai S; Samukawa Y
Adv Ther; 2016 Mar; 33(3):460-79. PubMed ID: 26846284
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet.
Nishimura R; Omiya H; Sugio K; Ubukata M; Sakai S; Samukawa Y
Diabetes Obes Metab; 2016 Jul; 18(7):702-6. PubMed ID: 26639943
[TBL] [Abstract][Full Text] [Related]
10. Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study.
Samukawa Y; Omiya H; Watase H; Nozaki K; Sakai S; Nishimura R
Adv Ther; 2016 Jul; 33(7):1215-30. PubMed ID: 27255763
[TBL] [Abstract][Full Text] [Related]
11. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice.
Okauchi S; Shimoda M; Obata A; Kimura T; Hirukawa H; Kohara K; Mune T; Kaku K; Kaneto H
Biochem Biophys Res Commun; 2016 Feb; 470(3):772-782. PubMed ID: 26505796
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.
Sasaki T; Seino Y; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Adv Ther; 2015 Apr; 32(4):319-40. PubMed ID: 25855342
[TBL] [Abstract][Full Text] [Related]
13. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Haneda M; Seino Y; Inagaki N; Kaku K; Sasaki T; Fukatsu A; Kakiuchi H; Sato Y; Sakai S; Samukawa Y
Clin Ther; 2016 Jan; 38(1):66-88.e20. PubMed ID: 26718606
[TBL] [Abstract][Full Text] [Related]
14. Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of Luseogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus.
Samukawa Y; Mutoh M; Chen S; Mizui N
Biol Pharm Bull; 2017; 40(8):1207-1218. PubMed ID: 28769002
[TBL] [Abstract][Full Text] [Related]
15. The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.
Nakatsu Y; Kokubo H; Bumdelger B; Yoshizumi M; Yamamotoya T; Matsunaga Y; Ueda K; Inoue Y; Inoue MK; Fujishiro M; Kushiyama A; Ono H; Sakoda H; Asano T
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28777298
[TBL] [Abstract][Full Text] [Related]
16. SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan.
Ito H; Shinozaki M; Nishio S; Abe M
Expert Opin Pharmacother; 2016 Oct; 17(15):2073-84. PubMed ID: 27592508
[TBL] [Abstract][Full Text] [Related]
17. Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.
Sasaki T; Seino Y; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Adv Ther; 2015 May; 32(5):404-17. PubMed ID: 25975816
[TBL] [Abstract][Full Text] [Related]
18. In vitro characterization of luseogliflozin, a potent and competitive sodium glucose co-transporter 2 inhibitor: Inhibition kinetics and binding studies.
Uchida S; Mitani A; Gunji E; Takahashi T; Yamamoto K
J Pharmacol Sci; 2015 May; 128(1):54-7. PubMed ID: 26003086
[TBL] [Abstract][Full Text] [Related]
19. Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study.
Nishimura R; Osonoi T; Kanada S; Jinnouchi H; Sugio K; Omiya H; Ubukata M; Sakai S; Samukawa Y
Diabetes Obes Metab; 2015 Aug; 17(8):800-4. PubMed ID: 25930989
[TBL] [Abstract][Full Text] [Related]
20. Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Seino Y; Kaku K; Inagaki N; Haneda M; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Endocr J; 2015; 62(7):593-603. PubMed ID: 25971406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]